Navigation Links
Inostics' Blood-based Mutation Testing Receives CLIA Certification
Date:5/30/2013

BALTIMORE, May 30, 2013 /PRNewswire/ --

Inostics, a molecular diagnostics company that provides blood-based mutation testing, received CLIA (Clinical Laboratory Improvement Amendments) licensure for its clinical laboratory located in Baltimore, MD. This marks a critical milestone for the clinical adoption of this non-invasive molecular approach for the analysis of tumor biomarkers.

"Due to the non-invasiveness and real-time reflection of tumor genetics, the OncoBEAM blood test represents a valuable tool to complement clinical decision making. We are extremely excited to be able to bring this solution to cancer patients as OncoBEAM tests offer a significant enhancement to clinical care over traditional tissue-based molecular testing," Dr. Frank Diehl , CSO of Inostics, said.

The OncoBEAM blood test is based on BEAMing technology which combines emulsion based digital PCR with flow cytometry. This technology enables the molecular analysis of tumor DNA shed from primary and metastatic tumors, found circulating in the blood of patients. Due to its non-invasiveness, OncoBEAM blood tests introduce new possibilities for the management of various cancers like skin, colorectal, breast, and lung cancer. Now a simple blood draw can support clinical decision making in the context of therapy selection, assessment of drug response, resistance and recurrence monitoring, and detection of minimal residual disease (MRD).  

About Inostics

Inostics is a molecular service company whose core competency is mutation detection utilizing highly sensitive technologies such as BEAMing and Plasma-Sequencing. In addition to the CLIA services, Inostics serves pharmaceutical companies and researchers with testing services for plasma/serum and tissue samples in the field of clinical trials and research in oncology. Inostics' headquarters are located in Hamburg, Germany and Inostics Clinical Laboratory is located at the Science and Technology Park at Johns Hopkins in Baltimore, Maryland.

For more information on OncoBEAM blood testing and the BEAMing technology refer to http://www.clinical.inostics.com or email lab@inostics.com.

Press contact:
Inostics
Friederike Lehmann , PhD
Marketing & Licensing
Phone +49-(0)40-413383-90
Fax +49-(0)40-413383-99
lehmann@inostics.com
http://www.inostics.com


'/>"/>
SOURCE Inostics GmbH
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inostics DNA Blood Test Provides a More Precise Picture of Resistance Mutations Than Traditional Biopsies
2. DioGenix and Fast Forward Collaborate to Develop Blood-Based Molecular Diagnostic for Multiple Sclerosis
3. Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
4. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
5. Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
6. Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
7. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
8. Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
9. Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests
10. SMT C1100 For Duchenne Muscular Dystrophy Moves To Human Testing
11. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
Breaking Medicine News(10 mins):